Midterm Results of Drug-Coated Balloon and Bare Metal Stent in the Treatment of TASCII C/D Femoropopliteal Artery Occlusive Disease: A Retrospective Multicenter Study

Abstract

Purpose:

This study aimed to compare midterm efficacy between drug-coated balloon (DCB) and bare metal stent (BMS) in the treatment of TASCII C/D femoropopliteal artery lesions.

Methods:

The clinical data of patients with TASCII C/D femoropopliteal artery disease admitted to 3 vascular surgery centers from January 2018 to January 2021 were retrospectively analyzed. Patients were divided into DCB group and BMS group. The DCB group was further subdivided into DCB alone subgroup and DCB+BMS subgroup. Study primary outcomes were freedom from clinical-driven target lesion reintervention (FCD-TLR) at 24 months postprocedure. Secondary outcomes included ankle brachial index (ABI), Rutherford classification, major amputation rate, and mortality.

Results:

A total of 410 consecutive patients were enrolled. At 24 months follow-up, in DCB group (114 patients) relative to BMS group (296 patients), FCD-TLR (86.00% vs 71.91%, p=0.039), and ABI (0.53±0.11 vs 0.47±0.19, p=0.007) were higher; mean Rutherford class was lower (1.57±0.68 vs 3.31±1.39, p=0.000); and major amputation rate (0.87% vs 4.05%, p>0.05) and all-cause mortality (8.92% vs 6.41%, p>0.05) were statistically similar. In DCB alone, subgroup relative to DCB+BMS subgroup, FCD-TLR (90.00% vs 85.00%, p>0.05), major amputation rate (0 vs 1.08%, p>0.05), and all-cause mortality rate (9.09% vs 8.69%, p>0.05) were statistically similar, while FCD-TLR was higher in the DCB+BMS subgroup (90.00% vs 71.91%, p=0.045).

Conclusion:

At midterm follow-up of patients treated for TASCII C/D femoropopliteal artery disease, use of DCB or of DCB combined with rescue BMS appeared similarly efficacious, and yielded more favorable outcomes than use of BMS.

Clinical Impact

The efficacy of drug-coated balloons relative to that of bare metal stents for the treatment of complex femoropopliteal artery lesions, particularly TASCII grade D lesions, remains uncertain. There is a scarcity of multicenter comparative studies, and in this multicenter retrospective study with up to 24-month follow-up, use of drug-coated balloon alone or combined with rescue bare metal stent appeared similarly efficacious while yielding more favorable outcomes than use of bare metal stent alone in the treatment of TASCII grade C/D femoropopliteal artery lesions. Randomized studies are warranted.

Keywords

complicated femoropopliteal artery lesions TASCII C/D drug-coated balloon bare metal stents Rescue stent

Get full access to this article

View all access options for this article.

References

Hess

Hiatt

WR.

Antithrombotic therapy for peripheral artery disease in 2018. JAMA. 2018;319(22):2329–2330. doi:10.1001/jama.2018.5422.

Criqui

Aboyans

Epidemiology of peripheral artery disease. Circ Res. 2015;116(9):1509–1526. doi:10.1161/CIRCRESAHA.l16.303849.

Gerhard-Herman

Gornik

Barrett

, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2017;69(11):e71–e126.

Aboyans

Bjorck

Brodmann

, et al. Questions and answers on diagnosis and management of patients with peripheral arterial diseases: a companion document of the 2017 ESC guidelines for the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018;55(4):457–464. doi:10.1016/j.ejvs.2017.08.014.

Zeller

Dake

Tepe

, et al. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents. JACC Cardiovasc Interv. 2013;6(3):274–281. doi:10.1016/j.jcin.2012.12.118.

Setacci

Chisci

de Donato

, et al. Subintimal angioplasty with the aid of a re-entry device for TASC C and D lesions of the SFA. Eur J Vasc Endovasc Surg. 2009;38(1):76–87. doi:10.1016/j.ejvs.2009.03.020.

Markose

Miller

Bolia

Subintimal angioplasty for femoro-popliteal occlusive disease. J Vasc Surg. 2010;52(5):1410–1416. doi:10.1016/j.jvs.2010.03.046.

Selmon

Schwindt

Cawich

, et al. Final results of the Chronic Total Occlusion Crossing With the Ocelot System II (CONNECT II) study. J Endovasc Ther. 2013;20(6):770–781. doi:10.1583/13-4380MR.1.

Bradbury

Moakes

Popplewell

, et al. A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial. Lancet. 2023;401(10390):1798–1809. doi:10.1016/S0140-6736(23)00462-2.

10.

Aboyans

Ricco

J-B

Bartelink

MEL

, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO) the task force for the diagnosis and treatment of peripheral arterial diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763–816. doi:10.1093/eurheartj/ehx095.

11.

Tosaka

Soga

Iida

, et al. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2012;59(1):16–23. doi:10.1016/j.jacc.2011.09.036.

12.

Liao

Song

, et al. Randomized controlled trial of orchid drug-coated balloon versus standard percutaneous transluminal angioplasty for treatment of femoropopliteal artery in-stent restenosis. Int Angiol. 2019;38(5):365–371. doi:10.23736/S0392-9590.19.04243-3.

13.

Scheinert

Sax

, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45(2):312–315. doi:10.1016/j.jacc.2004.11.026.

14.

Tepe

Laird Schneider

, et al.Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease 12-month results from the IN..PACT SFA randomized trial. Circulation. 2015;131(5):495–502. doi:10.1161/CIRCULAT1ONAHA.114.011004.

15.

Krishnan

Fanes

Niazi

, et al. Stellarex drug-coated balloon for treatment of femoropopliteal disease twelve-month outcomes from the randomized ILLUMENATE Pivotal and Pharmacokinetic Studies. Circulation. 2017;136(12):1102–1113. doi:10.1161/CIRCULAT1ONAHA.117.028893.

16.

Rosenfield

Jaff

White

, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373(2):145–153. doi:10.1056/NEJMoal406235.

17.

Stoner

Calligaro

Chaer

, et al. Reporting standards of the Society for Vascular Surgery for endovascular treatment of chronic lower extremity peripheral coronary artery disease. J Vasc Surg. 2016;64(1):e1–e21. doi:10.1016/j.jvs.2016.03.420.

18.

Baril

Chaer

Rhee

, et al. Endovascular interventions for TASC II D femoropopliteal lesions. J Vasc Surg. 2010;51(6):1406–1412. doi:10.1016/j.jvs.2010.01.062.

19.

Yin

Jiang

Huang

, et al. Endovascular interventions for TransAtlantic InterSociety Consensus II C and D femoropopliteal lesions. Chin Med J (Engl). 2013;126(3):415–420.

20.

Sabeti

Mlekusch

Amighi

, et al. Primary patency of long segment self-expanding nitinol stents in the femoropopliteal arteries. J Endovasc Ther. 2005;12(1):6–12. doi:10.1583/04-1359.1.

21.

Yue

Xiang

Daqiao

, et al. Efficacy comparison of drug-coated balloon combined with stent implantation and conventional balloon combined with stent implantation in the treatment of TASC grade D femoropopliteal artery disease. Chin J General Surgery. 2022;37(1):21–25. doi:10.3760/ cma.j.cn113855-20210124-00053.

22.

Schillinger

Sabeti

Loewe

, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354(18):1879–1888. doi:10.1056/NEJMoa051303.

23.

Laird

Katzen

Scheinert

, et al.Nitinol stent implantation vs. Balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther. 2012;19(1):1–9. doi:10.1583/11-3627.1.

24.

Schillinger

Sabeti

Dick

, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115:2745–2749. doi:10.1161/CIRCULATIONAHA.107.688341.

25.

Bosiers

Deloose

Callaert

, et al. Results of the protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions. J Vasc Surg. 2011;54(4):1042–1050. doi:10.1016/j.jvs.2011.03.272.

26.

Elmahdy

Buonamici

Trapani

, et al. Long-term primary patency rate after nitinol self-expandable stents implantation in long, totally occluded femoropopliteal (TASC II C & D) lesions. Heart Lung Circ. 2017;26(6):604–611. doi:10.1016/j.hlc.2016.09.011.

27.

Giannopoulos

Lyden

Bisdas

, et al. Endovascular intervention for the treatment of Trans-Atlantic Inter-Society Consensus (TASC) D femoropopliteal lesions: a systematic review and meta-analysis. Cardiovasc Revasc Med. 2021;22:52–65. doi:10.1016/j.carrev.2020.06.014.

28.

Schmidt

Fiorkowski

Gorner

, et al. Drug-coated balloons for complex femoropopliteal lesions: 2–year results of a real–world registry. JACC Cardiovasc Interv. 2016;9(7):715–724. doi:10.1016/j.jcin.2015.12.267.

29.

Micari

Vadala

Castriota

, et al. 1-year results of paclitaxel-coated balloons for long femoropopliteal artery disease: evidence from the SFA-LONG study. JACC Cardiovasc Interv. 2016;9(9):950–956. doi:10.1016/j.jcin.2016.02.014.

30.

Micari

Nerla

Vadala

, et al. 2-year results of paclitaxel-coated balloons for long femoropopliteal artery disease: evidence from the SFA-LONG study. JACC Cardiovasc Interv. 2017;10(7):728–734. doi:10.1016/j.jcin.2017.01.028.

31.

Kokkinidis

Jeon-Slaughter

Khalili

, et al. Adjunctive stent use during endovascular intervention to the femoropopliteal artery with drug coated balloons: insights from the XLPAD registry. Vasc Med. 2018;23(4):358–364. doi:10.1177/1358863X18775593.

32.

Zeller

Rastan

Macharzina

, et al. Drug coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions. J Endovasc Ther. 2014;21(3):359–368. doi:10.1583/13-4630MR.1.